Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.55 |
| ▸ | CTSC | P53634 | 2/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.51 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30054155 | 0.94 | MME (0.56) | MMEOPRM1OPRD1CTSCPSMB5 | |
| SCHEMBL29402842 | 0.93 | OPRD1 (0.64) | MMEOPRM1OPRD1 | |
| SCHEMBL30799615 | 0.93 | MME (0.55) | MMEOPRM1OPRD1CTSC | |
| SCHEMBL29658158 | 0.91 | MME (0.50) | MMEOPRM1OPRD1CTSCPSMB5 | |
| SCHEMBL30051626 | 0.91 | CTSD (0.57) | MMECTSCPSMB5CTSDCTSL | |
| SCHEMBL29527180 | 0.90 | OPRD1 (0.58) | MMEOPRM1OPRD1 | |
| SCHEMBL11059164 | 0.88 | CTSD (0.59) | MMEPSMB5CTSD | |
| SCHEMBL11059196 | 0.88 | CTSD (0.59) | MMEPSMB5CTSD | |
| SCHEMBL29784904 | 0.86 | BACE1 (0.47) | MMEOPRM1OPRD1PSMB5CTSD | |
| SCHEMBL30055181 | 0.86 | MME (0.49) | MMEOPRM1OPRD1CTSCCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11860174-B2 | Anti-cannabidiol antibody and uses thereof | Bomi LLC (US) | 2024-01-02 | — | — | US | disclosed |
| CN-114478789-A | anti-PD-L1 and OX40 bispecific antibodies and uses thereof | 安徽安科生物工程（集团）股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11860174-B2 | Anti-cannabidiol antibody and uses thereof | CNR2, CNR1, MAG | MME 1840/4885OPRM1 415/4885OPRD1 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.